Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Ovarian Cancer|Endometrial Cancer
Interventions: DRUG: ARQ 092 + carboplatin + paclitaxel (Closed)|DRUG: ARQ 092 + paclitaxel (Closed)|DRUG: ARQ 092 + anastrozole
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)